Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IAPs as a target for anticancer therapy.

S Danson1, E Dean, C Dive

  • 1Christie Hospital NHS Trust and Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, United Kingdom. s.danson@sheffield.ac.uk

Current Cancer Drug Targets
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.

Gynecologic oncology·2024
Same author

Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.

Immuno-oncology technology·2024
Same author

Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.

ESMO open·2022
Same author

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

iRFP (near-infrared fluorescent protein) imaging of subcutaneous and deep tissue tumours in mice highlights differences between imaging platforms.

Cancer cell international·2021
Same journal

Coordinated Roles of T Cells and Natural Killer Cells in Tumor Immunity.

Current cancer drug targets·2026
Same journal

Multi-omics Signature Predicts Anti-EGFR Therapy Benefit in Colorectal Cancer Liver Metastases: A Multi-center Cohort Study.

Current cancer drug targets·2026
Same journal

Anticancer Effect and Mechanism of Novel c-Myc Inhibitor BP1 on Hepatocellular Carcinoma.

Current cancer drug targets·2026
Same journal

Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer.

Current cancer drug targets·2026
Same journal

Corrigendum to: Migrasomes: A Novel Target for Cancer Treatment.

Current cancer drug targets·2026
Same journal

Corrigendum to: GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells.

Current cancer drug targets·2026
See all related articles

Targeting X-linked inhibitor of apoptosis protein (XIAP) is a promising cancer therapy. Inhibiting XIAP can re-sensitize tumors to chemotherapy and radiotherapy, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cancer cells evade apoptosis, a key mechanism for cell death, leading to treatment failure.
  • X-linked inhibitor of apoptosis protein (XIAP) is overexpressed in many cancers, inhibiting caspases and suppressing apoptosis.
  • XIAP overexpression correlates with resistance to chemotherapy and radiotherapy, impacting clinical outcomes.

Purpose of the Study:

  • To review preclinical data on inhibiting XIAP using antisense oligonucleotides (ASO) and small molecule inhibitors.
  • To discuss emerging Phase I clinical trial data for XIAP inhibitors.
  • To explore future strategies for XIAP manipulation and clinical development.

Main Methods:

  • Review of preclinical studies on XIAP antagonists (ASO and small molecules).

Related Experiment Videos

  • Analysis of in vitro data showing XIAP knockdown, apoptosis induction, and sensitization to cytotoxic drugs.
  • Evaluation of in vivo data demonstrating antitumour effects and chemosensitization.

    • Main Results:

    • XIAP antagonists effectively induce apoptosis and sensitize tumor cells to radiotherapy and chemotherapy in vitro.
    • In vivo studies show XIAP antagonists possess antitumour effects and enhance chemotherapy efficacy.
    • Emerging Phase I clinical data are being discussed, indicating potential therapeutic applications.

    Conclusions:

    • Inhibiting XIAP, a key regulator in the final common pathway of apoptosis, is a viable therapeutic strategy.
    • XIAP antagonists, including ASOs and small molecules, show promise in preclinical models.
    • Targeting XIAP offers a novel approach to overcome chemotherapy resistance and improve cancer treatment outcomes.